IP Library Granted Patent US 10,160,970
Granted Patent B2
US 10,160,970 · App. 15/557,164 · Granted Dec 25, 2018

Methods and pharmaceutical compositions for the treatment of filovirus infections

Inventors: Samir Amrane (Pessac, FR); Jean-Louis Mergny (Pessac, FR); Amina Bedrat (Pessac, FR)
Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); UNIVERSITÉ DE BORDEAUX
C12N15/1131A61K38/162A61K47/6929C12N15/115C12N2310/13C12N2310/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,160,970
App. No.
15/557,164
Granted
Dec 25, 2018
Kind
B2
Abstract

The present invention relates to methods and pharmaceutical compositions for the treatment of filovirus infections. In particular, the present invention relates to a method of treating filovirus infection in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one oligonucleotide comprising the sequence as set forth in SEQ ID NO:1 to SEQ ID NO:15.

Claims (6)

1. An oligonucleotide comprising a sequence as set forth in SEQ ID NO:2 to SEQ ID NO:15, wherein said oligonucleotide is conjugated to at least one nanoparticle.

2. The oligonucleotide of claim 1 , wherein said at least one nanoparticle is a gold nanoparticle.

3. A plasmid consisting of a sequence as set forth in SEQ ID NO:2 to SEQ ID NO:15 and a heterologous nucleic acid sequence.

4. A pharmaceutical composition comprising an oligonucleotide comprising a sequence as set forth in SEQ ID NO:2 to SEQ ID NO:15 and a pharmaceutically acceptable carrier selected from the group consisting of sodium chloride, colloidal silica, talc, a polymeric carrier, a cellulose-based compound, polyvinylpyrrolidone, polyacrylates, and polyethylene glycol.

5. The pharmaceutical composition of claim 4 , wherein said oligonucleotide is conjugated to at least one nanoparticle.

6. The pharmaceutical composition of claim 5 , wherein said at least one nanoparticle is a gold nanoparticle.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 4, 2017
From: AMRANE, SAMIR; MERGNY, JEAN-LOUIS; BEDRAT, AMINA
To: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE); UNIVERSITÉ DE BORDEAUX
Reel/Frame 043778/0069 →
Priority Claims (1)
EP 15305367 · Mar 11, 2015 · regional
Continuity (1)
Related Publication 20180051288A1 · Feb 22, 2018